Wang Xi, Ni Jing, Hsu Chen-Long, Johnykutty Sharlin, Tang Ping, Ho Yuan-Soon, Lee Chia-Hwa, Yeh Shuyuang
Department of Pathology and Laboratory Medicine, University of Rochester Medical School, Rochester, New York, USA.
Cancer Invest. 2009 Dec;27(10):971-7. doi: 10.3109/07357900802392659.
We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57% of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80% in high grade invasive carcinomas (p < .01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ (DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.
我们发现，与肺、结肠和肾脏相比，TAP/Sec14L2在正常/良性乳腺、前列腺和肝脏组织中高表达。通过定量PCR显示，其在乳腺癌细胞系中的表达下调。此外，141例人类浸润性乳腺癌中有57%经免疫组化染色显示TAP/Sec14L2表达缺失或显著降低，在高级别浸润性癌中这一比例增至80%（p < .01）。TAP/Sec14L2的这种下调在与浸润性癌相关的导管原位癌（DCIS）中也存在。这些发现提示TAP/Sec14L2可能在乳腺癌发生过程中作为一种肿瘤抑制因子发挥作用。
